FFO
PCVX icon

Fortitude Family Office’s Vaxcyte PCVX Stock Holding History

Fortitude Family Office’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$639 Sell
11
-9
-45% -$489 ﹤0.01% 1914
2026
Q1 		$1.16K Buy
20
+10
+100% +$543 ﹤0.01% 1468
2025
Q4 		$461 Buy
+10
New +$447 ﹤0.01% 1746
2025
Q2 		– Sell
-26
Closed -$982 – 2103
2025
Q1 		$982 Hold
26
– – ﹤0.01% 1021
2024
Q4 		$2.13K Hold
26
– – ﹤0.01% 1024
2024
Q3 		$2.97K Hold
26
– – ﹤0.01% 926
2024
Q2 		$1.96K Buy
26
+9
+53% +$613 ﹤0.01% 808
2024
Q1 		$1.16K Hold
17
– – ﹤0.01% 896
2023
Q4 		$1.07K Buy
+17
New +$883 ﹤0.01% 939

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fortitude Family Office's PCVX Position: Q2 2026 in Review

Fortitude Family Office reduced its Vaxcyte (PCVX) stake by 45% in Q2 2026, selling an estimated $489 and leaving 11 shares worth $639. The position accounts for ﹤0.01% of the portfolio, ranked #1914.

Fortitude Family Office first reported a position in PCVX in Q4 2023 and has held it in 9 quarters since. The position peaked at $2.97K in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Fortitude Family Office held 11 shares of Vaxcyte worth $639 as of Q2 2026.
  • Fortitude Family Office sold 9 Vaxcyte shares in Q2 2026, an estimated $489.
  • Vaxcyte made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1914 holding.
  • Fortitude Family Office first reported a position in Vaxcyte in Q4 2023 and has held it in 9 quarters since.
  • Fortitude Family Office's Vaxcyte position peaked at $2.97K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.